SYT yields 0.27% · ABBV yields 3.06%● Live data
📍 SYT pulled ahead of the other in Year 9
Combined, SYT + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SYT + ABBV for your $10,000?
SYLA Technologies Co., Ltd., through its subsidiaries, primarily develops, constructs, sells, and manages apartments in Japan. It also engages in the land purchase, design, construction, operation, and maintenance of solar power plants. In addition, it offers real estate leasing, brokerage, and management services; and real estate crowdfunding service on the Rimawari-kun platform. Further, the company designs, develops, manufactures, and sells computers for artificial intelligence (AI) and graphics processing, as well as offers computer maintenance and management services; Rimawari-kun AI, a system that automatically collects various real estate data found online and compiles indexes; real estate investment, machine learning algorithms, robotic process automation, and business systems using the system. Additionally, it provides consulting on business automation and AI system implementation for corporations; offers consulting on real estate investment and asset management; operates and sells renewable energy data centers; and sells and maintains solar and biomass power generation equipment. The company also engages in electricity brokerage, renewable energy trading, and trade brokerage activities. The company was formerly known as SYLA Holdings Co., Ltd. SYLA Technologies Co., Ltd. was incorporated in 2009 and is headquartered in Tokyo, Japan.
Full SYT Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.